Tumor necrosis factor-α in a porcine bronchial model of obliterative bronchiolitis

Transplantation

Volumn 76, Issue 3, 2003, Pages 516-523

  Alho, Hanni S ^a   Maasilta, Paula K ^a   Harjula, Ari L J ^a   Hämmäinen, Pekka ^a   Salminen, Jukka ^a   Salminen, Ulla Stina ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CYTOKINE; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ALLOGRAFT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOGRAFT; BRONCHIOLITIS; BRONCHUS; CELL DAMAGE; CELL PROLIFERATION; EPITHELIUM CELL; FIBROBLAST; FIBROSIS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INFLAMMATORY CELL; LUNG TRANSPLANTATION; LYMPHOCYTE; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; SMALL AIRWAY DISEASE; SWINE;

ANIMALS; ANTIBODIES, MONOCLONAL; BRONCHI; BRONCHIOLITIS OBLITERANS; CD8-POSITIVE T-LYMPHOCYTES; IMMUNOHISTOCHEMISTRY; INFLAMMATION; POSTOPERATIVE COMPLICATIONS; SWINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0042968643     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000074700.30536.76     Document Type: Article

References (33)

1. Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care Med 2002; 166: 440.
2. Boehler A, Bai XH, Liu M, et al. Upregulation of T-helper 1 cytokines and chemokine expression in post-transplant airway obliteration. Am J Respir Crit Care Med 1999; 159: 1910.
3. Neuringer IP, Walsh SP, Mannon RP, et al. Enhanced T cell cytokine gene expression in mouse airway obliterative bronchiolitis. Transplantation 2000; 69: 399.
4. Beutler B, Cerami A. Tumor necrosis, cachexia, shock, and inflammation: A common mediator. Annu Rev Biochem 1988; 57: 505.
5. Strieter RM, Lukacs NW, Kunkel SL. Role of adhesion molecules and cytokines in lung transplantation. In: Ward PA, Fantone JC, eds. Adhesion molecules and the lung. New York, Marcel Dekker 1996, p 279.
6. Saito R, Prehn J, Zuo XJ, et al. The participation of tumor necrosis factor in the pathogenesis of lung allograft rejection in the rat. Transplantation 1993: 55; 967.
7. DeMeester SR, Rolfe MW, Kunkel SL, et al. The bimodal expression of tumor necrosis factor-alpha in association with rat lung reimplantation and allograft rejection. J Immunol 1993: 150; 2494.
8. Magnan A, Mege JL, Reynaud M, et al. Monitoring of alveolar macrophage production of tumor necrosis factor-alpha and interleukin-6 in lung transplant recipients: Marseille and Montreal lung transplantation group. Am J Respir Crit Care Med 1994: 150; 684.
9. Sekine Y, Bowen LK, Heidler KM, et al. Role of passenger leukocytes in allograft rejection: Effect of depletion of donor alveolar macrophages on the local production of TNF alpha, T helper 1/T helper 2 cytokines, IgG subclasses, and pathology in a rat model of lung transplantation. J Immunol 1997; 159: 4084.
10. Smith CR, Jaramillo A, Lu KC, et al. Prevention of obliterative airway disease in HLA-A2-transgenic tracheal allografts by neutralizing of tumor necrosis factor. Transplantation 2001: 72; 1512.
11. Aris RM, Walsh S, Chalermskulrat W, et al. Growth factor upregulation during obliterative bronchiolitis in the mouse model. Am J Respir Crit Care Med 2002: 166; 417.
12. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: What have we learned? Annu Rev Immunol 2001: 19; 163.
13. Uusitalo MH, Salminen US, Ikonen TS, et al. Alloimmune injury preceding airway obliteration in porcine heterotopic lung implants: A histologic and immunohistologic study. Transplantation 1999; 68: 970.
14. Maasilta PK, Salminen US, Lautenschlager IT, et al. Immune cells and immunosuppression in a porcine bronchial model of obliterative bronchiolitis. Transplantation 2001; 72: 998.
15. Su X, Prestwood AK, Otto CM, et al. Monoclonal antibodies to porcine tumor necrosis factor alpha: Development of an enzyme-linked immunosorbent assay. J Immunoassay 1992; 13: 253.
16. Reinsmoen NL, Bolman RM, Savik K, et al. Are multiple immunopathogenetic events occurring during the development of obliterative bronchiolitis and acute rejection. Transplantation 1993; 55: 1040.
17. Neuringer IP, Mannon RB, Coffman TM, et al. Immune cells in a mouse model of obliterative bronchiolitis. Am J Respir Cell Mol Biol 1998; 19: 379.
18. Kollias G, Douni E, Kassiotis G, et al. On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol Rev 1999; 169: 175.
19. Scheurich P, Thoma B, Ucer U, et al. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: Induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses. J Immunol 1987; 138: 1786.
20. Sedgwick JD, Riminton DS, Cyster JG, et al. Tumor necrosis factor: A master regulator of leukocyte movement. Immunol Today 2000; 21: 110.
21. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000: 343; 1594.
22. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002: 359; 1541.
23. Kuhnert P, Wüthrich C, Peterhans E, et al. The porcine tumor necrosis factor encoding genes: Sequence and comparative analysis. Gene 1991; 102: 171.
24. Olmarker K, Rydevik B. Selective inhibition of tumor necrosis factor-α prevents nucleus pulposus-induced thrombus formation, intraneural edema, and reduction of nerve conduction velocity. Spine 2001; 26: 863.
25. Kulmatycki KM, Abouchehade K, Sattari S, et al. Drug-disease interaction: Reduced β-adrenergic and potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions in the rat. Br J Pharm 2001; 133: 286.
26. Vassallo R, Matteson E, Thomas CF Jr. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest 2002; 122: 1093.
27. Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995; 7: 251.
28. Taylor PC, Peters AM, Paleolog E, et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000; 43: 38.
29. Maini RN, Taylor PC, Paleolog E, et al. Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Ann Rheum Dis 1999; 58(suppl): 156.
30. Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha-therapy in rheumatoid arthritis. J Immunol 1999; 163: 1521.
31. Brass DM, Hoyle GW, Poovey HG, et al. Reduced tumor necrosis factor-alpha and transforming growth factor-beta1 expression in the lungs of inbred mice that fail to develop fibroproliferative lesions consequent to asbestos exposure. Am J Pathol 1999; 154: 853.
32. Cornillie F, Shealy D, Haens GD, et al. Infliximab induces potent antiinflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 2001; 15: 463.
33. Kavanaugh A, St Clair EW, McCune WJ, et al. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000; 27: 841.